{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:42:03Z","timestamp":1793821323225,"version":"4.6.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"DOI":"10.1186\/s13065-026-01839-5","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T01:54:11Z","timestamp":1780797251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and bioanalytical validation of a high-sensitivity LC-MS\/MS assay for quantitative determination of sotagliflozin in rabbit plasma and its stability across controlled storage conditions"],"prefix":"10.1186","volume":"20","author":[{"given":"Smit Jayantilal","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiralben","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basheer Ahmmad","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"key":"1839_CR1","doi-asserted-by":"crossref","unstructured":"American Diabetes Association, 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018; 41: S73-S85.","DOI":"10.2337\/dc18-S008"},{"issue":"11","key":"1839_CR2","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.4103\/jfmpc.jfmpc_843_20","volume":"9","author":"S Kalra","year":"2020","unstructured":"Kalra S, Das AK, Priya G, et al. Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel. J Family Med Prim Care Nov. 2020;9(11):5450\u2013457. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_843_20.","journal-title":"J Family Med Prim Care Nov"},{"issue":"2","key":"1839_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/jdi.12693","volume":"9","author":"N Fujita","year":"2017","unstructured":"Fujita N, Yamamoto Y, et al. Real-life glycemic control in patients with type 2 diabetes treated with insulin therapy: A prospective, longitudinal cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT 9]). J Diabetes Invest Jun. 2017;9(2):294\u2013302. https:\/\/doi.org\/10.1111\/jdi.12693.","journal-title":"J Diabetes Invest Jun"},{"issue":"11","key":"1839_CR4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1152\/ajprenal.00267.2015","volume":"309","author":"MA Abdul-Ghani","year":"2015","unstructured":"Abdul-Ghani MA, Norton L, et al. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiology-Renal Physiol Sep. 2015;309(11):889\u2013900. https:\/\/doi.org\/10.1152\/ajprenal.00267.2015.","journal-title":"Am J Physiology-Renal Physiol Sep"},{"issue":"1","key":"1839_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/2314808X.2022.2145734","volume":"10","author":"S Batra","year":"2022","unstructured":"Batra S, Bamrah PK, Choudhary M. Sodium-glucose transporter (SGLT2) inhibition: A potential target for treatment of type-2 Diabetes Mellitus with Natural and Synthetic compounds. Egypt J Basic Appl Sci Nov. 2022;10(1):69\u201382. https:\/\/doi.org\/10.1080\/2314808X.2022.2145734.","journal-title":"Egypt J Basic Appl Sci Nov"},{"issue":"16","key":"1839_CR6","doi-asserted-by":"publisher","first-page":"10848","DOI":"10.1021\/acs.jmedchem.2c00867","volume":"65","author":"R Maccari","year":"2022","unstructured":"Maccari R, Ottan\u00e0 R. Sodium glucose cotransporter inhibitors as antidiabetic drugs: current development and future perspectives. J Med Chem Aug. 2022;65(16):10848\u2013881. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00867.","journal-title":"J Med Chem Aug"},{"key":"1839_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejps.2016.08.025","volume":"93","author":"T Madaan","year":"2016","unstructured":"Madaan T, Akhtar M, Najmi AK. Sodium glucose cotransporter 2 (SGLT2) inhibitors: current status and future perspective. Eur J Pharm Sci Oct. 2016;93:244\u201352. https:\/\/doi.org\/10.1016\/j.ejps.2016.08.025.","journal-title":"Eur J Pharm Sci Oct"},{"issue":"20","key":"1839_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0828-y","volume":"18","author":"CMA Cefalo","year":"2019","unstructured":"Cefalo CMA, Cinti F, Moffa S, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol Feb. 2019;18(20):1\u201314. https:\/\/doi.org\/10.1186\/s12933-019-0828-y.","journal-title":"Cardiovasc Diabetol Feb"},{"issue":"3","key":"1839_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.5281\/zenodo.15561449","volume":"4","author":"H Uppada","year":"2025","unstructured":"Uppada H, Boddapu D, Bonula H. Development and validation of UV spectrometric method for determination of sotagliflozin. World J Pharm Sci Res May. 2025;4(3):114\u201320. https:\/\/doi.org\/10.5281\/zenodo.15561449.","journal-title":"World J Pharm Sci Res May"},{"issue":"7","key":"1839_CR10","first-page":"776","volume":"3","author":"A Yadav","year":"2025","unstructured":"Yadav A, Barsagade A. RP-HPLC based analytical method development and validation of sotaglifloizn in pharmaceutical dosage form. Int J Pharm Sci Jul. 2025;3(7):776\u201379.","journal-title":"Int J Pharm Sci Jul"},{"key":"1839_CR11","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.2147\/DDDT.S372575","volume":"16","author":"X He","year":"2022","unstructured":"He X, Gao X, Xie P, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of sotagliflozin after multiple ascending doses in chinese healthy subjects. Drug Des Dev Therapy Sep. 2022;16:2967\u2013980. https:\/\/doi.org\/10.2147\/DDDT.S372575.","journal-title":"Drug Des Dev Therapy Sep"},{"issue":"2","key":"1839_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.13005\/ojc\/410238","volume":"41","author":"B Chatterjee","year":"2025","unstructured":"Chatterjee B, Mondal P, Acharyya S. Advanced UPLC-photo diode array method for precise quantification of sotagliflozin in bulk and commercial formulations. Orient J Chem Mar. 2025;41(2):689\u201396. https:\/\/doi.org\/10.13005\/ojc\/410238.","journal-title":"Orient J Chem Mar"},{"key":"1839_CR13","unstructured":"ICH guideline M10 on bioanalytical method validation. and study sample analysis. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf (accessed on November 05, 2025)."},{"issue":"10","key":"1839_CR14","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.52711\/0974-360X.2024.00771","volume":"17","author":"SJ Patel","year":"2024","unstructured":"Patel SJ, Chauhan B, Shaikh B, Chavan P, Khan N. Development and validation of selective and sensitive liquid chromatography - tandem mass spectroscopy (UHPLC-MS\/MS) method for bioanalysis of remogliflozin in rat plasma. Res J Pharm Technol. 2024;17(10):5016\u201320. https:\/\/doi.org\/10.52711\/0974-360X.2024.00771.","journal-title":"Res J Pharm Technol"},{"issue":"2","key":"1839_CR15","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.5958\/0974-360X.2021.00187.6","volume":"14","author":"M Merugu","year":"2021","unstructured":"Merugu M, Vijey AM. Stability indicating simultaneous method development and validation of dapagliflozin and saxagliptin by RP-HPLC. Res J Pharm Technol Feb. 2021;14(2):1045\u20139. https:\/\/doi.org\/10.5958\/0974-360X.2021.00187.6.","journal-title":"Res J Pharm Technol Feb"},{"issue":"8","key":"1839_CR16","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.52711\/0974-360X.2025.00532","volume":"18","author":"SB Baokar","year":"2025","unstructured":"Baokar SB, Patil RN, Pandey AN. Bioanalytical method development and validation for the estimation of metformin and empagliflozin in blood plasma by using RP-HPLC. Res J Pharm Technol Sep. 2025;18(8):3699\u2013702. https:\/\/doi.org\/10.52711\/0974-360X.2025.00532.","journal-title":"Res J Pharm Technol Sep"},{"issue":"2","key":"1839_CR17","doi-asserted-by":"publisher","first-page":"789","DOI":"10.52711\/0974-360X.2024.00122","volume":"17","author":"N Tamilselvi","year":"2024","unstructured":"Tamilselvi N, Kanagapriya K. Bioequivalence study and bioanalytical method development of remogliflozin etabonate tablets in wistar rat plasma using RP-HPLC method. Res J Pharm Technol Feb. 2024;17(2):789\u201394. https:\/\/doi.org\/10.52711\/0974-360X.2024.00122.","journal-title":"Res J Pharm Technol Feb"},{"key":"1839_CR18","doi-asserted-by":"publisher","unstructured":"Locatelli M, Abuzar K, Perrucci M. et. al. Recent trends in sampling and sorbent-based sample preparation procedures for bioanalytical applications. Microchemical J Dec. 2024;207. https:\/\/doi.org\/10.1016\/j.microc.2024.111903.","DOI":"10.1016\/j.microc.2024.111903"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-026-01839-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-026-01839-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-026-01839-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:27:26Z","timestamp":1786501646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13065-026-01839-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1186\/s13065-026-01839-5","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,7]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"173"}}